Watch KAPA. Know when insiders buy.
One email the day a filing lands. Free.
KAPA
Kairos Pharma, LTD.
0.50
+0.03 +6.54%
USD · close Nov 3
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
26
FLAG · shorts 26
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $12MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$5.8MNET CASH —52W 0.47 – 6.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.4M | −$1.4M | — | -0.06 | −$1M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$1.7M | −$1.7M | — | -0.08 | −$1M | — | — | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.4M | −$1.4M | — | -0.07 | −$1.1M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$1.4M | −$1.4M | — | -0.07 | −$838K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$1.5M | −$1.4M | — | -0.08 | −$805K | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$1.3M | −$1.3M | — | -0.08 | −$714K | — | — | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.4M | −$980K | — | -0.08 | −$1.8M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$383K | −$1M | — | -0.10 | −$2M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$222K | −$253K | — | -0.02 | −$168K | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$287K | −$323K | — | -0.03 | $36K | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.1M | −$1.1M | — | -0.10 | $66K | — | — | Apr 15 |
| Q3 2023 · Sep 30 | — | — | — | −$287K | −$312K | — | -0.03 | — | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$5.6M | −$5.4M | — | -0.30 | −$3.4M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$2.3M | −$2.6M | — | -0.23 | −$4M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$1.7M | −$1.8M | — | -0.17 | $81K | — | — | — | — |
Every number comes from Kairos Pharma, LTD.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.